Navigation Links
UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth
Date:11/8/2010

NEW YORK, Nov. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

http://www.reportlinker.com/p0207247/UK-Pharmaceutical-Market-Overview---Pricing-and-reimbursement-challenges-dampen-future-growth.html

IntroductionThe UK prescription pharmaceutical market was valued at $28.4 billion in 2009. Key growth drivers include growing use of chronic high-value innovative treatments driven by a rising elderly population, high public healthcare expenditure as proportion of total healthcare expenditure, relatively light pricing controls through the PPRS, and speedy domestic drug approvals.

Scope*Overview of the UK's socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position

*Assesses the size of the UK's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

*Examines the UK's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

*Quantifies the UK's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.

HighlightsThe UK pharmaceutical industry has to some extent been cushioned from the effects of the recession. However, the NHS now faces cuts and with price cuts to be implemented in Southern Europe further stimulating the parallel exportation of drugs out of these markets, branded drug sales in the UK market will certainly be impacted.

The UK's Department of Health is considering imposing mandatory generic substitution at the pharmacist level, as part of the renegotiated PPRS which came into effect in 2009. Mandatory substitution should boost generics volume uptake in the UK, but the extent of the increase is likely to be limited, given the widespread use of generics in the UK.

The UK has a strong track record for drug development. However, Roche and Novartis have threatened to pull out of the UK due to ongoing debates over drug pricing, expensive and bureaucratic clinical trials, and recent non-approval decisions by NICE. Also, a number of key players are downsizing their UK operations in an effort to reduce costs.

Reasons to Purchase*Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.

*Quantify the size and growth of the prescription pharmaceutical market in the UK, analyzing key therapy areas, brands and companies.

*Assess drivers and resistors of generic and biosimilars uptake in the UK as well as the level of erosion brands can expect to face post patent expiry.

ABOUT DATAMONITOR HEALTHCARE 2

About the Healthcare Strategic Analysis Team 2

Country specific reports: 2

Global issue reports: 2

1. Executive Summary 3

Strategic scoping and focus 3

Key findings - UK healthcare drivers and resistors 4

Socio-demographic and economic analysis 8

UK socio-demographic trends 8

UK socio-economic trends 8

Healthcare system and drug regulatory analysis 10

UK healthcare expenditure 10

UK healthcare system overview 11

UK regulatory issues 11

UK pricing and reimbursement issues 11

Prescription pharmaceutical sales analysis 13

UK pharmaceutical market size 13

UK leading therapy areas 13

UK leading prescription pharmaceutical brands 13

UK pharmaceutical companies 13

Drug expiry analysis 15

UK generics market 15

UK brand erosion post patent expiry 15

UK biosimilars market 15

Pharmaceutical industry infrastructure analysis 17

UK pharmaceutical industry infrastructure overview 17

UK R&D infrastructure trends 17

UK manufacturing infrastructure trends 18

Related reports 20

Upcoming related reports 20

Table of Contents 21

2. Socio-demographic and economic analysis 22

Key findings 22

UK socio-demographic trends 22

UK socio-economic trends 22

Demographic trends in the UK 23

UK population growth rate expected to slow 24

Birth rate in UK is declining 26

Proportion of elderly people in the UK expected to rise and then level off 27

Life expectancy will continue to increase in the UK and across other markets 28

Disease burden in the UK 29

Ischemic heart disease is the leading cause of death in the UK 29

Non-communicable diseases are the main cause of overall disease burden in the UK 31

Communicable diseases are a relatively uncommon cause of death in the UK, but healthcare-associated infections are on the rise 32

Political climate in the UK 33

The recent general election has resulted in a change of ruling political party and the formation of a coalition government 33

UK economy still vulnerable after recession 34

Pharma has historically been relatively well insulated from the recession, but the NHS could face cuts 36

The UK has high standards of living, but there are income inequalities 37

Business environment in the UK 37

UK corporate tax rate one of the lowest in the EU 37

Unemployment rate is high 38

3. Healthcare system and drug regulatory analysis 39

Key findings 39

UK healthcare expenditure 39

UK healthcare system 39

UK regulatory issues 39

UK pricing and reimbursement issues 40

Healthcare expenditure - UK lags behind most developed nations 41

Healthcare system in the UK 43

NHS is the main healthcare provider in the UK 43

A number of stakeholders exist within the NHS 44

Investment in the NHS has risen substantially over the last decade, but cuts loom 46

UK is lagging behind other countries in health outcomes 46

Private healthcare provision is supplementary to the NHS 47

Primary versus hospital care - the number of hospital beds is falling in the UK as community care becomes more prominent 48

Healthcare system reform in the UK 48

Regulatory issues in the UK 50

Drug approval and regulatory processes 50

MHRA is the national body in charge of regulating medicines 50

Cost of regulatory filings varies according to type of authorization procedure used 51

UK's MHRA boasts short approval times 52

The application process in the UK is straightforward 53

UK license holders must report adverse drug reactions to EudraVigilance 54

New initiatives aim to reduce regulatory burdens on Pharma 54

The EU centralized procedure is convenient but expensive 54

Decentralized procedure introduced to address disputes in mutual recognition procedure 55

Country order of launch - brands tend to launch early in the UK 55

Intellectual property environment ? UK court determines validity of patents in the UK 56

High number of patent litigations and expensive fees but litigation times are short 56

Supplementary protection certificates give extra protection 57

Data exclusivity issues in the UK - the 8+2+1 rule 57

Pediatric SPC extension provides additional market exclusivity period 58

Drug counterfeiting - UK is becoming an easy target for counterfeiters 58

Drug importation in the UK ? companies wishing to import or export medicines must have licenses 59

Although the UK is generally a target country for parallel trade a recent surge in parallel exports has led to shortages of medicines 60

Pricing and reimbursement in the UK 62

Pricing issues in the UK 64

PPRS is a light form of pricing regulation 64

2009 PPRS introduced flexible pricing to reward innovation 66

Value-based pricing in the future? 66

UK drug prices among lowest in Western markets as a result of weak pound 67

Discounts obtained by hospitals, PCTs and pharmacies add further complexity to determining UK drug prices 68

Reimbursement issues in the UK 68

NICE is the key reimbursement body in the UK 68

SMC is NICE's equivalent in Scotland 69

Cost-effectiveness analysis forms the basis of NICE's appraisal 69

NICE appraises only a subset of drugs 71

NICE's review process - thorough but lengthy 72

Patient empowerment can have an impact on NICE reviews 73

Time delays caused by NICE are a significant issue 74

NICE has issued a number of controversial decisions and negative guidance over the past few years 74

Lack of transparency and over-reliance on QALY draws criticism from pharma industry 75

NICE's appraisal process prompted parliamentary review 76

Risk-sharing schemes are becoming the norm for expensive drugs 77

End-of-life guidance does not guarantee NICE approval 79

Better access to drugs on the horizon in the UK? 80

Will the new cancer drug fund improve access to cancer treatments in the UK? 81

Other pricing and reimbursement issues in the UK 81

Prescription charges do not have a significant impact on which drug is dispensed 81

Top-up payments have been introduced recently but used mostly for drugs not approved by NICE 81

4. Prescription pharmaceutical sales analysis 82

Key findings 82

Pharmaceutical market size in the UK 83

Leading therapy areas in the UK 85

Central nervous system drugs hold the largest share of the UK market value 87

Oncology drugs exhibited the strongest sales during 2005-09 88

Immunology and inflammation drugs showed the fastest sales growth between 2008 and 2009 88

Gastroenterology and cardiovascular drugs saw declining sales 88

Leading prescription pharmaceutical brands in the UK 90

Leading brand Seretide may face competition from faster-growing Symbicort 91

Lipitor has begun to suffer from sales erosion from other generic statins 91

Enbrel's solid growth is attributed to its superior efficacy and having secured approval for multiple indications 91

Leading pharmaceutical companies in the UK prescription pharmaceutical market 94

The leading international companies struggle to maintain growth momentum 95

The leading domestic companies experience impressive growth 98

GlaxoSmithKline 99

AstraZeneca 100

Shire 100

5. Drug expiry analysis 101

Key findings 101

UK generics market 101

UK brand erosion post patent expiry 101

UK biosimilars market 101

UK generics market dynamics 103

UK generics volume uptake 104

UK generics value uptake 105

UK generics market size 106

Drivers and resistors in the UK generics market 107

The proportion of prescribed and dispensed generic drugs has been steadily rising in the UK 108

The government is looking to impose mandatory generic substitution to further drive generic uptake 109

Improved efficiency in generic pricing across PCTs could significantly cut drug costs 110

Savings achievable through increased generic statin use have made them a target for cost-cutting initiatives 110

Large price differential between brands and generics is indicative of a commodity generics market in the UK 111

Key generics players in the UK market 113

Opportunities for the generics industry 114

Small molecule brand erosion in the UK 116

Overview of drugs analyzed 116

Mean level of brand erosion in the UK 117

Brand erosion in the UK retail and hospital setting 118

Brand erosion by therapy area in the UK 120

Brand erosion by drug formulation in the UK 122

UK biosimilars market dynamics 124

Drivers and resistors to biosimilar uptake in the UK - hospital purchasing decisions pivotal to driving biosimilar uptake 124

Key players in the UK biosimilars market 125

Biosimilar epoetin 125

Epoetin volume and value market share 126

Branded epoetin prices in the UK market post biosimilar entry 128

Biosimilar epoetin market share 129

Biosimilar filgrastim 130

Filgrastim volume and value market share 130

Branded filgrastim prices in the UK market post biosimilar entry 132

Biosimilar filgrastim market share 134

Biosimilar somatropin 135

Somatropin volume and value market share 136

New and future biosimilar launches 138

Opportunities for the biosimilars industry 139

Branded monoclonal antibody therapies could soon face biosimilar incursion 142

Biosimilars in development internationally 143

6. Pharmaceutical industry infrastructure analysis 145

Key findings 145

UK pharmaceutical industry infrastructure overview 145

UK R&D infrastructure trends 145

UK manufacturing infrastructure trends 145

UK pharmaceutical industry infrastructure overview 147

R&D and manufacturing strategies in the UK 147

R&D operations downsized to produce more focused pipeline offering higher returns 148

Manufacturers reduce investment in UK facilities and look to outsourcing 149

Key company infrastructure in the UK 149

Pfizer 150

Pfizer's acquisition and integration of Wyeth has resulted in the closure of two R&D sites 153

Pfizer phases out manufacturing in the UK 153

Pfizer enhances its biotech capabilities through M&A activity 155

GlaxoSmithKline 156

GlaxoSmithKline restructures to focus on rare diseases, downsizing R&D in the UK 158

Two manufacturing plants to shut due to lower demand as a result of generic competition 159

Berkshire Hathaway buys a small stake in GlaxoSmithKline 161

Sanofi-Aventis 162

Sanofi-Aventis restructures, cutting R&D spend in favor of R&D partnership agreements 164

Lower demand for maturing drugs leads to closure of a UK manufacturing plant 164

Sanofi-Aventis's acquisition of Acambis expands its vaccines offering 166

AstraZeneca 167

AstraZeneca to implement heavy cuts in R&D workforce 169

Manufacturing capabilities replaced by outsourcing 169

Merck & Co. 171

Roche 175

Roche's strengthens its pipeline with promising early-stage compounds 179

Johnson & Johnson 180

DePuy strengthens its hip implants offering through the acquisition of Finsbury Orthopaedics 182

Eli Lilly 184

Novartis 188

UK manufacturing site helped Novartis reach record sales in 2009 190

Latest restructuring plan has created a leaner operating environment 191

Boehringer Ingelheim 192

7. Bibliography 196

Executive summary 196

Publications and online articles 196

Datamonitor reports and products 196

Socio-demographic and Economic analysis 196

Publications and online articles 196

Datamonitor reports and products 198

Healthcare system & drug regulation 198

Publications and online articles 198

Datamonitor reports and products 204

Pharmaceutical sales analysis 205

Publications and online articles 205

Datamonitor reports and products 205

Drug expiry analysis 205

Publications and online articles 205

Datamonitor reports and products 208

Industry infrastructure analysis 209

Publications and online articles 209

Datamonitor reports and products 211

APPENDIX 212

Exchange rates 212

UK brand erosion - additional data and analysis 213

UK brand erosion - methodology 215

UK brand erosion - therapy area classification 217

About Datamonitor 218

About Datamonitor Healthcare 218

Datamonitor consulting 218

Disclaimer 220

List of Tables

Table 1: UK - changes in the key value drivers of the UK pharmaceutical market, 2005-09 6

Table 2: UK - demographic indicators, 2005 and 2010 8

Table 3: UK - key economic indicators, 2005-2012 9

Table 4: UK - healthcare expenditure indicators, 2006-09 10

Table 5: UK - pricing and reimbursement tools, 2010 12

Table 6: UK - sales and volume of the prescription pharmaceutical market ($ and IMS Standard Units), 2009 14

Table 7: UK - key metrics for the generics and biosimilars market, 2010 16

Table 8: UK - pharmaceutical industry metrics, 2007-09 17

Table 9: UK - R&D and manufacturing infrastructure mean data for top 10 pharma companies in the UK, 2008-2010 19

Table 10: UK - demographic indicators, 2005 and 2010 23

Table 11: UK - top 10 causes of mortality, 2004 29

Table 12: UK - disability-adjusted life years (DALY) rates compared to Australia, Japan, the BRIC nations, North America and other key European markets, 2004 31

Table 13: UK - key economic indicators, 2005-2012 34

Table 14: UK - healthcare expenditure indicators, 2006-09 42

Table 15: UK - hospital bed and healthcare worker density, 2002 and 2007 48

Table 16: UK - fees payable to Medicines and Healthcare products Regulatory Agency (MHRA). 2010 51

Table 17: Order of launch for new molecules in the US, Japan, France, Germany, Italy, Spain, UK, Canada and Australia 55

Table 18: UK - a range of pricing and reimbursement tools are used 62

Table 19: UK - Pharmaceutical Price Regulation Scheme (PPRS) mandated price adjustments, 2009-2013 65

Table 20: UK - comparison of ex-manufacturer prices in the UK with selected developed nations, 2004-08 67

Table 21: UK - NICE has rejected a number of drugs on the basis of poor cost-effectiveness 75

Table 22: UK - risk-sharing agreements companies entered into with NICE, 2009-2010 77

Table 23: UK - sales and volume of the prescription pharmaceutical market ($ and IMS Standard Units), 2009 84

Table 24: UK - pharmaceutical sales by therapy area ($m and %), 2005-09 86

Table 25: UK - pharmaceutical volume by therapy area (SUm and %), 2005-09 87

Table 26: UK - sales growth for top 20 pharmaceutical brands ($m and %), 2009 92

Table 27: UK - volume growth for top 20 pharmaceutical brands (SUm and %), 2009 93

Table 28: UK - sales growth for the leading international pharmaceutical companies ($ and %), 2009 96

Table 29: UK - volume growth for the leading international pharmaceutical companies in the UK (SU and %), 2009 97

Table 30: UK - sales growth for the leading UK-based pharmaceutical companies ($ and %), 2009 98

Table 31: UK - volume growth for the leading UK-based pharmaceutical companies (SU and %), 2009 99

Table 32: UK - key metrics for the generics and biosimilars market, 2010 102

Table 33: UK - comparison of generic penetration versus other major pharmaceutical markets ($ billion and %), 2007-08 103

Table 34: UK - leading generics companies, 2009 113

Table 35: UK - brands exposed to generic competition, 2010-12 114

Table 36: UK - key metrics for the biosimilars market, 2009 124

Table 37: UK - leading biosimilar companies, 2009 125

Table 38: Biosimilars approved and rejected in Europe by the European Medicines Agency (EMA) to May 2010 138

Table 39: UK - sales (based on 2009 sales data) of biologics both expired and expected to come off-patent in 2010-15 141

Table 40: UK - pharmaceutical industry metrics, 2007-09 147

Table 41: UK - prescription sales growth for the top 10 pharmaceutical companies ($m and %), 2009 149

Table 42: UK - Pfizer's R&D and manufacturing infrastructure (post-merger with Wyeth), 2010 150

Table 43: UK - Pfizer's R&D and manufacturing infrastructure data (post-merger with Wyeth), 2010 151

Table 44: UK - Pfizer's UK-based M&A activity, 2008-2010 155

Table 45: UK - GlaxoSmithKline's R&D and manufacturing infrastructure, 2010 156

Table 46: UK - GlaxoSmithKline's R&D and manufacturing infrastructure data, 2010 157

Table 47: UK - GlaxoSmithKline's UK-based M&A activity, 2008-2010 161

Table 48: UK - Sanofi-Aventis's R&D and manufacturing infrastructure, 2010 162

Table 49: UK - Sanofi-Aventis's R&D and manufacturing infrastructure data, 2010 163

Table 50: UK - Sanofi-Aventis's UK-based M&A activity, 2008-2010 166

Table 51: UK - AstraZeneca's R&D and manufacturing infrastructure, 2010 167

Table 52: UK - AstraZeneca's R&D and manufacturing infrastructure data, 2010 168

Table 53: UK - Merck & Co's R&D and manufacturing infrastructure (post acquisition of Schering-Plough), 2010 171

Table 54: UK - Merck & Co's R&D and manufacturing infrastructure data (post acquisition of Schering-Plough), 2010 172

Table 55: UK - Roche's R&D and manufacturing infrastructure, 2010 175

Table 56: UK - Roche's R&D and manufacturing infrastructure data, 2010 176

Table 57: UK - Roche's UK-based M&A activity, 2008-2010 179

Table 58: UK - Johnson & Johnson's R&D and manufacturing infrastructure, 2010 180

Table 59: UK - Johnson & Johnson's R&D and manufacturing infrastructure data, 2010 181

Table 60: UK - Johnson & Johnson's UK-based M&A activity, 2008-2010 183

Table 61: UK - Eli Lilly's R&D and manufacturing infrastructure, 2010 184

Table 62: UK - Eli Lilly R&D and manufacturing infrastructure data, 2010 185

Table 63: UK - Novartis's R&D and manufacturing infrastructure, 2010 188

Table 64: UK - Novartis's R&D and manufacturing infrastructure data, 2010 189

Table 65: UK - Boehringer Ingelheim's R&D and manufacturing infrastructure, 2010 192

Table 66: UK - Boehringer Ingelheim's R&D and manufacturing infrastructure data, 2010 193

Table 67: Currency exchange rates, 2010 212

Table 68: ATC (anatomical therapeutic chemical) classification codes assigned to a given therapy area 217

List of Figures

Figure 1: UK - key value drivers of the UK pharmaceutical market, 2009 4

Figure 2: UK - drivers and resistors facing branded pharmaceutical companies 7

Figure 3: UK - population and population growth rate, 1950-2050 24

Figure 4: UK - population growth compared to the other seven major markets, Australia, Japan, the BRIC nations, North America and other key European markets, 1950-2050 25

Figure 5: UK - birth rates per 1,000 individuals compared to the other seven major markets, Australia, Japan, the BRIC nations, North America and other key European markets, 1950-2050 26

Figure 6: UK - proportion of population over 65 years compared to the other seven major markets, Australia, Japan, the BRIC nations, North America and other key European markets, 1950-2050 27

Figure 7: UK - life expectancy compared to the other seven major markets, Australia, Japan, the BRIC nations, North America and other key European markets, 1950-2050 28

Figure 8: UK - GDP per capita growth rate compared to, Australia, Japan, the BRIC nations, North America and other key European markets, 2005-09 35

Figure 9: Debt trap rankings for the UK, France, Germany, Italy, Spain, US, Canada, Australia and Japan, 2010 36

Figure 10: Unemployment rates in the UK, France, Germany, Italy, Spain, US, Canada, Australia, Japan, Brazil, India, Russia and China, 1990-2008 38

Figure 11: UK - the proportion of GDP expenditure on healthcare is lower compared to most other developed nations, 2007 41

Figure 12: UK - flow of money and accountability within the National Health Service (NHS) 44

Figure 13: UK - primary care trusts (PCTs) are the key stakeholders within the National Health Service (NHS) 45

Figure 14: UK - structure of the private healthcare system 47

Figure 15: UK - four routes for obtaining market authorization in the UK 51

Figure 16: UK - Medicines and Healthcare products Regulatory Agency (MHRA) application process 53

Figure 17: EU - the 8+2+1 market exclusivity rule 57

Figure 18: UK - a number of different bodies impact drug prescription and use 63

Figure 19: UK - advantages and disadvantages of the Pharmaceutical Price Regulation Scheme (PPRS) for the UK pharmaceutical industry 66

Figure 20: UK - NICE's topic selection process 71

Figure 21: UK - NICE's review process 73

Figure 22: UK - drivers and resistors of entering into risk-sharing agreements 78

Figure 23: UK - three new schemes aim to improve access to drugs, 2010 80

Figure 24: UK - relative sales and volume of the UK prescription pharmaceutical market (indexed against volume or value in 2005), 2005-09 83

Figure 25: UK - pharmaceutical sales by therapy area (%), 2005-09 85

Figure 26: UK - sales growth for the leading pharmaceutical brands ($m and %), 2009 90

Figure 27: UK - sales growth for leading pharmaceutical companies (%), 2005-09 94

Figure 28: UK - comparison of generic volume uptake versus other major pharmaceutical markets (%), 2007-08 104

Figure 29: UK - comparison of generic value uptake versus other major pharmaceutical markets (%), 2007-08 105

Figure 30: UK - comparison of generics market size versus other pharmaceutical markets ($ billion), 2007-08 106

Figure 31: UK - key factors influencing the UK generic industry, 2010 107

Figure 32: England - generic prescribing and dispensing (%), 1998-2008 108

Figure 33: UK - brand sales at risk of generic erosion ($m), 2010-12 115

Figure 34: UK - mean erosion (by value and volume) of branded small molecules during the first 2 years of generic competition (%) 117

Figure 35: UK - mean erosion (by value and volume) of branded small molecules by prescribing setting during the first 2 years of generic competition 119

Figure 36: UK - mean erosion (by value and volume) of branded small molecules by therapy area during the first 2 years of generic competition 121

Figure 37: UK - mean erosion (by value and volume) of branded small molecules by formulation during the first 2 years of generic competition 123

Figure 38: UK - biosimilar versus branded epoetin alpha volume uptake (%), 2009 126

Figure 39: UK - biosimilar versus branded epoetin alpha value uptake (%), 2009 127

Figure 40: UK - unit price for Aranesp, NeoRecormon and Eprex, 2008-09 128

Figure 41: UK - biosimilar epoetin market share by volume (%), 2008-09 129

Figure 42: UK - biosimilar versus branded filgrastim volume uptake (%), 2008-09 130

Figure 43: UK - biosimilar versus branded filgrastim value uptake (%), 2008-09 131

Figure 44: UK - unit price for Neupogen and Granocyte ($/SU), 2008-09 132

Figure 45: UK - unit price for Neulasta ($/SU), 2008-09 133

Figure 46: UK - biosimilar versus branded filgrastim market share by volume (%), 2008-09 134

Figure 47: UK - biosimilar versus branded somatropin volume uptake (%), 2006-09 136

Figure 48: UK - biosimilar versus branded somatropin value uptake (%), 2006-09 137

Figure 49: UK - sales (based on 2009 sales data) of biologics both expired and expected to come off-patent during 2010-15 140

Figure 50: Drivers and resistors to biosimilar monoclonal antibody entry, 2010 143

Figure 51: Key biosimilars in development internationally by product class, 2010 144

Figure 52: Pharma's strategic responses to slowing sales and operating profit growth 148

Figure 53: UK - Pfizer's R&D presence (post-merger with Wyeth), 2010 152

Figure 54: UK - Pfizer's pharmaceutical operations (post-merger with Wyeth), 2010 154

Figure 55: UK - GlaxoSmithKline's R&D and manufacturing presence, 2010 158

Figure 56: UK - GlaxoSmithKline's pharmaceutical operations, 2010 160

Figure 57: UK - Sanofi-Aventis's R&D presence, 2010 164

Figure 58: UK - Sanofi-Aventis's pharmaceutical operations, 2010 165

Figure 59: UK - AstraZeneca's R&D and manufacturing presence, 2010 169

Figure 60: UK - AstraZeneca's pharmaceutical operations, 2010 170

Figure 61: UK - Merck & Co's R&D and manufacturing presence (post acquisition of Schering-Plough), 2010 173

Figure 62: UK - Merck & Co's pharmaceutical operations (post acquisition of Schering-Plough), 2010 174

Figure 63: UK - Roche's R&D presence, 2010 177

Figure 64: UK - Roche's pharmaceutical operations, 2010 178

Figure 65: UK - Johnson & Johnson's pharmaceutical operations, 2010 182

Figure 66: UK - Eli Lilly's R&D and manufacturing presence, 2010 186

Figure 67: UK - Eli Lilly's pharmaceutical operations, 2010 187

Figure 68: UK - Novartis's R&D presence, 2010 190

Figure 69: UK - Novartis's pharmaceutical operations, 2010 191

Figure 70: UK - Boehringer Ingelheim's R&D and manufacturing presence, 2010 194

Figure 71: UK - Boehringer Ingelheim's pharmaceutical operations, 2010 195

Figure 72: UK - sales erosion of branded small molecules during the first 2 years of generic competition 213

Figure 73: UK - volume erosion of branded small molecules during the first 2 years of generic competition 214

Figure 74: Drugs experiencing generic erosion between Q1 2006 and Q2 2007 215

Figure 75: Erosion curves for each drug experiencing generic entry 216

Figure 76: Mean erosion curve for drugs A, B, and C experiencing generic entry 217

To order this report:Pharmaceutical Industry: UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET
2. EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist
3. Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
4. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
5. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
6. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
7. Penwest Pharmaceuticals Shareholders Approve Merger With Subsidiary of Endo Pharmaceuticals
8. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
10. Onyx Pharmaceuticals to Present at the Credit Suisse 2010 Healthcare Conference
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):